Mazdutide
$100.00
What is Mazdutide?
Mazdutide (IBI362/LY3305677) is a long-acting dual agonist of GLP-1 and glucagon receptors, developed as an acylated analog of oxyntomodulin (OXM). Oxyntomodulin is a naturally occurring gut hormone that activates both GLP-1R and GCGR, but has a very short half-life. Mazdutide was engineered with a C18 fatty acid acylation to enable albumin binding and extend its pharmacokinetic profile for once-weekly dosing. The dual GLP-1R/GCGR agonism provides complementary mechanisms: GLP-1R activation promotes satiety and glucose-dependent insulin secretion, while GCGR activation increases hepatic fatty acid oxidation and energy expenditure. Originally developed by Eli Lilly and licensed to Innovent Biologics for China development, mazdutide has been investigated in Phase 2 and Phase 3 clinical trials. It represents the dual agonist approach, distinguishing it from pure GLP-1 agonists (semaglutide) and triple agonists (retatrutide).
Mechanism of Action
Mazdutide has been investigated for its simultaneous activation of GLP-1 and glucagon receptors. At GLP-1R, mazdutide activates Gs-coupled cAMP signaling in pancreatic beta cells, potentiating glucose-dependent insulin secretion, and in hypothalamic neurons, promoting satiety. At the glucagon receptor (GCGR), mazdutide stimulates cAMP-dependent signaling in hepatocytes, activating pathways for glycogenolysis, gluconeogenesis, fatty acid oxidation, and thermogenesis. Researchers observed that the glucagon receptor component adds an energy expenditure mechanism absent from pure GLP-1R agonists — GCGR activation increases hepatic lipid oxidation and amino acid catabolism, contributing to negative energy balance. Studies suggest that the dual agonist approach balances the hyperglycemic potential of glucagon signaling with the glucose-lowering effect of GLP-1R activation, resulting in net glucose neutrality or improvement. The C18 fatty acid modification enables albumin binding, extending the half-life for once-weekly dosing similar to semaglutide.
Published Research
Phase 2 Clinical Data
Ji et al. (2023) reported results from a Phase 2 trial of mazdutide in Chinese adults with overweight or obesity. Researchers observed dose-dependent changes in body weight and metabolic parameters over 24 weeks, with the highest dose group showing significant reductions [1].
Oxyntomodulin Biology
Pocai A (2014) reviewed the biology of oxyntomodulin and the rationale for GLP-1/glucagon dual agonism, describing how the combination of incretin and glucagon signaling produces complementary metabolic effects [2].
Glucagon Receptor and Energy Expenditure
Habegger et al. (2010) characterized the role of glucagon receptor activation in energy metabolism, demonstrating that GCGR agonism increases hepatic fatty acid oxidation and thermogenesis in preclinical models [3].
Product Specifications
| Product | Mazdutide Lyophilized Powder |
|---|---|
| Available Sizes | 6mg |
| Purity | ≥99% (HPLC verified) |
| CAS Number | 2374817-17-1 |
| Sequence | Acylated oxyntomodulin analog (GLP-1/glucagon dual agonist with C18 fatty acid) |
| Molecular Formula | C₂₀₈H₃₁₂N₅₄O₆₅S₂ |
| Molecular Weight | 4,734.22 g/mol |
| Appearance | White lyophilized powder in glass vial |
| Storage | Store lyophilized at -20°C. Reconstituted solution at 2-8°C, use within 14 days. |
| Testing | Third-party tested — Certificate of Analysis available |
Frequently Asked Questions
Mazdutide (IBI362) is a long-acting dual GLP-1/glucagon receptor agonist based on an acylated oxyntomodulin analog. It activates two metabolic hormone receptors simultaneously.
The CAS registry number for Mazdutide is 2374817-17-1.
Semaglutide is a pure GLP-1R agonist. Mazdutide additionally activates the glucagon receptor, which adds hepatic lipid oxidation and energy expenditure mechanisms.
Store lyophilized Mazdutide at -20°C. Once reconstituted, store at 2-8°C and use within 14 days.
Oxyntomodulin is a naturally occurring gut hormone that activates both GLP-1 and glucagon receptors. Mazdutide is an engineered, long-acting analog of this hormone.
Mazdutide is a dual agonist (GLP-1R + GCGR). Retatrutide is a triple agonist (GLP-1R + GIPR + GCGR), adding GIP receptor activation to the profile.
References
- Ji L, et al. Efficacy and safety of mazdutide in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2023;11(4):245-255.
- Pocai A. Unraveling oxyntomodulin, GLP1's enigmatic brother. J Endocrinol. 2014;215(3):335-346. PMID: 23148202
- Habegger KM, et al. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010;6(12):689-697. PMID: 20957001
Customer Reviews
Professional packaging, fast delivery, great product.
Outstanding quality. This is my go-to source now.
Third order from Luxe — always reliable, always pure.
Product is great. Only minor delay in shipping.
Exactly what I needed for my research. Clean product.
Product arrived fast and in perfect condition.
Really happy with this. Clean, pure, well-packaged.
Fast shipping, well-packaged. Product quality is top-notch.
Nice quality. Website could use more research documentation.
Solid product quality. COA checks out perfectly.
Fast shipping, well-packaged. Product quality is top-notch.
Professional packaging, fast delivery, great product.
Reliable product. Took a bit longer to arrive than expected.
Verified purity matches the COA. Excellent.
Very pleased with this purchase. Will be a repeat customer.
